A review on side effect management of second-generation antipsychotics to treat schizophrenia: a drug safety perspective

References

• Stahl SM, Sy S, Maguire GA. How and when to treat the most common adverse effects of antipsychotics: expert review from research to clinical practice. Acta Psychiatr Scand. 2021 Feb;143(2):172–180. doi: 10.1111/acps.13266
   PubMed Web of Science ®Google Scholar
• Schneider-Thoma J, Chalkou K, Dorries C, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022 Feb 26;399(10327):824–836. doi: 10.1016/S0140-6736(21)01997-8
   PubMed Web of Science ®Google Scholar
• Beaudoin M, Hudon A, Giguere CE, et al. Prediction of quality of life in schizophrenia using machine learning models on data from clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial. Schizophrenia (Heidelb). 2022 Mar 21;8(1):29. doi: 10.1038/s41537-022-00236-w
   PubMedGoogle Scholar
• Dibonaventura M, Gabriel S, Dupclay L, et al. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012 Mar 20;12(1):20. doi: 10.1186/1471-244X-12-20
   PubMedGoogle Scholar
• Grunder G, Heinze M, Cordes J, et al. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry. 2016 Aug;3:(8):717–729.
   PubMed Web of Science ®Google Scholar
• Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015 Jun;114(1):169–179. doi: 10.1093/bmb/ldv017
   PubMed Web of Science ®Google Scholar
• German Society for Psychiatry, Psychotherapy and Neurology (DGPPN e.V.) (ed.) for the guideline group: S3 guideline schizophrenia. Long version, 2019, version 1.0, last modified March 15, 2019.
   Google Scholar
• SIGN G. Scottish intercollegiate guidelines network (SIGN). Management of attention deficit and hyperkinetic disorders in children and young people: a national clinical guideline. 2009:112.
   Google Scholar
• Health NCCfM. Psychosis and schizophrenia in adults: treatment and management. 2014.
   Google Scholar
• Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the british association for psychopharmacology. J Psychopharmacol. 2020 Jan;34:(1):3–78.
   PubMed Web of Science ®Google Scholar
• Salzmann-Erikson M, Sjodin M. A narrative meta-synthesis of how people with schizophrenia experience facilitators and barriers in using antipsychotic medication: implications for healthcare professionals. Int J Nurs Stud. 2018 Sep;85:7–18. doi: 10.1016/j.ijnurstu.2018.05.003
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Lehmann I, et al. Schizophrenia. Dtsch Arztebl Int. 2020 Jun 12;117(24):412–419. doi: 10.3238/arztebl.2020.0412
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019 Sep 14;394(10202):939–951. doi: 10.1016/S0140-6736(19)31135-3
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 Sep 14;382(9896):951–962. doi: 10.1016/S0140-6736(13)60733-3
   PubMed Web of Science ®Google Scholar
• Sabe M, Zhao N, Crippa A, et al. Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials. NPJ Schizophr. 2021 Sep 13;7(1):43. doi: 10.1038/s41537-021-00171-2
   PubMed Web of Science ®Google Scholar
• Zhu Y, Li C, Huhn M, et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017 Sep;27:(9):835–844.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209–1223. doi: 10.1056/NEJMoa051688
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008 Mar 29;371(9618):1085–1097. doi: 10.1016/S0140-6736(08)60486-9
   PubMed Web of Science ®Google Scholar
• Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry. 2006 Oct;63:(10):1079–1087.
   PubMed Web of Science ®Google Scholar
• Chen Z, Fan L, Wang H, et al. Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties. Nat Neurosci. 2022 Jan;25:(1):39–49.
   PubMed Web of Science ®Google Scholar
• Vasiliu O. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: what is the evidence? Front Psychiatry. 2022;13:1069432. doi: 10.3389/fpsyt.2022.1069432
   PubMed Web of Science ®Google Scholar
• McCutcheon RA, Harrison PJ, Howes OD, et al. Data-driven taxonomy for antipsychotic medication: a new classification system. Biol Psychiatry. 2023 Oct 1;94(7):561–568. doi: 10.1016/j.biopsych.2023.04.004
   PubMed Web of Science ®Google Scholar
• Correll CU, Abi-Dargham A, Howes O. Emerging treatments in schizophrenia. J Clin Psychiatry. 2022 Feb 15;83(1). doi: 10.4088/JCP.SU21024IP1
   Web of Science ®Google Scholar
• Brannan SK, Sawchak S, Miller AC, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021 Feb 25;384(8):717–726. doi: 10.1056/NEJMoa2017015
   PubMed Web of Science ®Google Scholar
• Dean B. Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal. Expert Opin Investig Drugs. 2023 Jul;32(12):1113–1121. doi: 10.1080/13543784.2023.2288074
   PubMed Web of Science ®Google Scholar
• Siafis S, Wu H, Wang D, et al. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry. 2023 Aug;28:(8):3267–3277.
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. 2012 Jan;38:(1):167–177.
   PubMed Web of Science ®Google Scholar
• Chang C-C, Chen H-K. The prevalence of constipation and its risk factors in patients with schizophrenia. Taiwan J Psychiatry. 2021;35(2):95–98. doi: 10.4103/tpsy.tpsy_20_21
   Google Scholar
• Chiappini S, Mosca A, Miuli A, et al. Misuse of anticholinergic medications: a systematic review. Biomedicines. 2022 Feb 1;10(2):355. doi: 10.3390/biomedicines10020355
   PubMed Web of Science ®Google Scholar
• Haddad C, Salameh P, Sacre H, et al. Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia. BMC Psychiatry. 2023 Jan 24;23(1):61. doi: 10.1186/s12888-023-04552-y
   PubMed Web of Science ®Google Scholar
• Joshi YB, Thomas ML, Braff DL, et al. Anticholinergic medication burden-associated cognitive impairment in schizophrenia. Am J Psychiatry. 2021 Sep 1;178(9):838–847. doi: 10.1176/appi.ajp.2020.20081212
   PubMed Web of Science ®Google Scholar
• Caroff SN, Citrome L, Meyer J, et al. A modified delphi consensus study of the screening, diagnosis, and treatment of Tardive Dyskinesia. J Clin Psychiatry. 2020 Jan 28;81(2). doi: 10.4088/JCP.19cs12983
   PubMed Web of Science ®Google Scholar
• Marzoughi S, Banerjee A, Jutzeler CR, et al. Tardive neurotoxicity of anticholinergic drugs: a review. J Neurochem. 2021 Sep;158:(6):1334–1344.
   PubMed Web of Science ®Google Scholar
• Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672–676. doi: 10.1192/bjp.154.5.672
   PubMed Web of Science ®Google Scholar
• Barnes TR. The Barnes akathisia rating scale–revisited. J Psychopharmacol. 2003;17(4):365–370. doi: 10.1177/0269881103174013
   PubMed Web of Science ®Google Scholar
• Gerlach J, Korsgaard S, Clemmesen P, et al. The st. Hans rating scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand. 1993;87(4):244–252. doi: 10.1111/j.1600-0447.1993.tb03366.x
   PubMed Web of Science ®Google Scholar
• Onishi H, Yoshioka A, Sato I, et al. Akathisia, an easily overlooked side effect. J Clin Oncol: Off J Am Society Clin Oncol. 2023 Jun 23;41(25):4184–4185. doi: 10.1200/jco.23.00853
   PubMed Web of Science ®Google Scholar
• Thompson H. Implementation of an akathisia scale into the mental health assessment to screen for early-onset akathisia. 2021.
   Google Scholar
• Bjarke J, Gjerde HN, Jorgensen HA, et al. Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial. Acta Neuropsychiatr. 2022 Oct;34:(5):282–288.
   PubMed Web of Science ®Google Scholar
• Wu H, Siafis S, Wang D, et al. Antipsychotic-induced akathisia in adults with acute schizophrenia: a systematic review and dose-response meta-analysis. Eur Neuropsychopharmacol. 2023 Jul;72:40–49. doi: 10.1016/j.euroneuro.2023.03.015
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Detraux J, Racagni G, et al. Medication-induced akathisia with newly approved antipsychotics in patients with a severe mental illness: a systematic review and meta-analysis. CNS Drugs. 2019 Jun;33:(6):549–566.
   PubMed Web of Science ®Google Scholar
• Salem H, Nagpal C, Pigott T, et al. Revisiting antipsychotic-induced akathisia: Current issues and prospective challenges. Curr Neuropharmacol. 2017;15(5):789–798. doi: 10.2174/1570159X14666161208153644
   PubMed Web of Science ®Google Scholar
• Musco S, McAllister V, Caudle I. Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment. Ther Adv Psychopharmacol. 2020;10:2045125320937575. doi: 10.1177/2045125320937575
   Web of Science ®Google Scholar
• Poyurovsky M, Weizman A. Treatment of Antipsychotic-Induced Akathisia: role of serotonin 5-HT(2a) receptor antagonists. Drugs. 2020 Jun;80(9):871–882. doi: 10.1007/s40265-020-01312-0
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Gardner D, Addington D, et al. The assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry. 2018 Nov;63:(11):719–729.
   PubMed Web of Science ®Google Scholar
• Zareifopoulos N, Katsaraki M, Stratos P, et al. Pathophysiology and management of akathisia 70 years after the introduction of the chlorpromazine, the first antipsychotic. Eur Rev Med Pharmacol Sci. 2021 Jan;25:(14):4746–4756.
   PubMed Web of Science ®Google Scholar
• Shams-Alizadeh N, Bakhshayesh H, Rezaei F, et al. Effect of vitamin B6 versus propranolol on antipsychotic-induced akathisia: a pilot comparative double-blind study. Iran J Pharm Res. 2018 Winter;17(Suppl):130–135.
   PubMedGoogle Scholar
• Carbon M, Hsieh CH, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017 Mar;78:(3):e264–e278.
   PubMed Web of Science ®Google Scholar
• Carbon M, Kane JM, Leucht S, et al. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018 Oct;17:(3):330–340.
   PubMed Web of Science ®Google Scholar
• Stegmayer K, Walther S, van Harten P. Tardive dyskinesia associated with atypical antipsychotics: prevalence, mechanisms and management strategies. CNS Drugs. 2018 Feb;32(2):135–147. doi: 10.1007/s40263-018-0494-8
   PubMed Web of Science ®Google Scholar
• Mentzel TQ, van der Snoek R, Lieverse R, et al. Clozapine monotherapy as a treatment for Antipsychotic-Induced Tardive Dyskinesia: a meta-analysis. J Clin Psychiatry. 2018 Sep 18;79(6). doi: 10.4088/JCP.17r11852
   PubMed Web of Science ®Google Scholar
• Pardis P, Remington G, Panda R, et al. Clozapine and tardive dyskinesia in patients with schizophrenia: a systematic review. J Psychopharmacol. 2019 Oct;33:(10):1187–1198.
   PubMed Web of Science ®Google Scholar
• Wong J, Pang T, Cheuk NKW, et al. A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders. Psychopharmacol (Berl). 2022 Nov;239:(11):3393–3420.
   PubMed Web of Science ®Google Scholar
• Dorfman BJ, Jimenez-Shahed J. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia. Expert Rev Neurother. 2021 Jan;21(1):9–20. doi: 10.1080/14737175.2021.1848548
   PubMed Web of Science ®Google Scholar
• Solmi M, Pigato G, Kane JM, et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215–1238. doi: 10.2147/DDDT.S133205
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Mori Y, Tsutsumi Y. Pathophysiology, prognosis and treatment of tardive dyskinesia. Ther Adv Psychopharmacol. 2022;12:20451253221117313. doi: 10.1177/20451253221117313
   Web of Science ®Google Scholar
• Szczakowska A, Gabryelska A, Gawlik-Kotelnicka O, et al. Deep brain stimulation in the treatment of tardive dyskinesia. J Clin Med. 2023;12(5):1868. doi: 10.3390/jcm12051868
   PubMed Web of Science ®Google Scholar
• Castle DJ, Buckley PF, Gaughran FP. Physical health and schizophrenia. Oxford: Oxford University Press; 2017. https://global.oup.com/academic/product/physical-health-and-schizophrenia-9780198811688?lang=en&cc=us
   Google Scholar
• Correll CU, Solmi M, Croatto G, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022 Jun;21:(2):248–271.
   PubMed Web of Science ®Google Scholar
• Doane MJ, Bessonova L, Friedler HS, et al. Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder. BMC Psychiatry. 2022 Feb 14;22(1):114. doi: 10.1186/s12888-022-03758-w
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010 Nov;123:(2–3):225–233.
   PubMed Web of Science ®Google Scholar
• Annamalai A, Tek C. An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists. Int J Endocrinol. 2015;2015:969182. doi: 10.1155/2015/969182
   PubMed Web of Science ®Google Scholar
• Bernardo M, Rico-Villademoros F, Garcia-Rizo C, et al. Real-world data on the adverse metabolic effects of second-generation antipsychotics and their potential determinants in adult patients: a systematic review of population-based studies. Adv Ther. 2021 May;38:(5):2491–2512.
   PubMed Web of Science ®Google Scholar
• Hirsch L, Patten SB, Bresee L, et al. Second-generation antipsychotics and metabolic side-effects: Canadian population-based study. BJPsych Open. 2018 Jul;4:(4):256–261.
   PubMed Web of Science ®Google Scholar
• Musil R, Obermeier M, Russ P, et al. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf. 2015 Jan;14:(1):73–96.
   PubMed Web of Science ®Google Scholar
• Galling B, Roldan A, Nielsen RE, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry. 2016 Mar;73:(3):247–259.
   PubMed Web of Science ®Google Scholar
• Garrido-Torres N, Rocha-Gonzalez I, Alameda L, et al. Metabolic syndrome in antipsychotic-naive patients with first-episode psychosis: a systematic review and meta-analysis. Psychol Med. 2021 Oct;51:(14):2307–2320.
   PubMed Web of Science ®Google Scholar
• Misiak B, Frydecka D, Laczmanski L, et al. Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients. Eur J Clin Pharmacol. 2014 Dec;70:(12):1433–1441.
   PubMed Web of Science ®Google Scholar
• Plosker GL, Deeks ED. Asenapine: a review in schizophrenia. CNS Drugs. 2016 Jul;30(7):655–666. doi: 10.1007/s40263-016-0363-2
   PubMed Web of Science ®Google Scholar
• Durgam S, Landbloom RP, Mackle M, et al. Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study. Neuropsychiatr Dis Treat. 2017;Volume 13:2021–2035. doi: 10.2147/NDT.S130211
   Web of Science ®Google Scholar
• Meyer JM, Ng-Mak DS, Chuang C-C, et al. Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records. Ann Gen Psychiatry. 2017;16(1):1–9. doi: 10.1186/s12991-017-0159-x
   PubMedGoogle Scholar
• Pochiero I, Calisti F, Comandini A, et al. Impact of lurasidone and other antipsychotics on body weight: real-world, retrospective, comparative study of 15,323 adults with schizophrenia. Int J Gene Med. 2021;Volume 14:4081–4094. doi: 10.2147/IJGM.S320611
   Web of Science ®Google Scholar
• Barton BB, Segger F, Fischer K, et al. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020 Mar;19:(3):295–314.
   PubMed Web of Science ®Google Scholar
• De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012 Sep 1;26(9):733–759. doi: 10.2165/11634500-000000000-00000
   PubMed Web of Science ®Google Scholar
• Cimo A, Stergiopoulos E, Cheng C, et al. Effective lifestyle interventions to improve type II diabetes self-management for those with schizophrenia or schizoaffective disorder: a systematic review. BMC Psychiatry. 2012 Mar 23;12(1):24. doi: 10.1186/1471-244X-12-24
   PubMedGoogle Scholar
• Marteene W, Winckel K, Hollingworth S, et al. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. Expert Opin Drug Saf. 2019 Dec;18:(12):1149–1160.
   PubMed Web of Science ®Google Scholar
• Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, et al. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008;193(2):101–107. doi: 10.1192/bjp.bp.107.042853
   PubMed Web of Science ®Google Scholar
• Teasdale SB, Ward PB, Rosenbaum S, et al. Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness. Br J Psychiatry. 2017;210(2):110–118. doi: 10.1192/bjp.bp.115.177139
   PubMed Web of Science ®Google Scholar
• Rosenbaum S, Tiedemann A, Sherrington C, et al. Physical activity interventions for people with mental illness: a systematic review and meta-analysis. J Clin Psychiatry. 2014;75(9):14465. doi: 10.4088/JCP.13r08765
   Web of Science ®Google Scholar
• Speyer H, Christian Brix Nørgaard H, Birk M, et al. The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity. World Psychiatry. 2016;15(2):155–165. doi: 10.1002/wps.20318
   PubMed Web of Science ®Google Scholar
• Green CA, Yarborough BJH, Leo MC, et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry. 2015;172(1):71–81. doi: 10.1176/appi.ajp.2014.14020173
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Vita G, Bertolini F, et al. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis. Lancet Psychiatry. 2022 Aug;9:(8):614–624.
   PubMed Web of Science ®Google Scholar
• Bak M, Drukker M, Cortenraad S, et al. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: a meta-analysis. PLoS One. 2021;16(2):e0244944. doi: 10.1371/journal.pone.0244944
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 Jan 3;373(9657):31–41. doi: 10.1016/S0140-6736(08)61764-X
   PubMed Web of Science ®Google Scholar
• de Silva VA, Suraweera C, Ratnatunga SS, et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016 Oct 3;16(1):341. doi: 10.1186/s12888-016-1049-5
   PubMedGoogle Scholar
• Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014 Nov;40:(6):1385–1403.
   PubMed Web of Science ®Google Scholar
• Siskind DJ, Leung J, Russell AW, et al. Metformin for clozapine associated obesity: a systematic review and meta-analysis. PLoS One. 2016;11(6):e0156208. doi: 10.1371/journal.pone.0156208
   PubMed Web of Science ®Google Scholar
• Fitzgerald I, O’Connell J, Keating D, et al. Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology. Evid Based Ment Health. 2022 Feb;25:(1):15–22.
   PubMed Web of Science ®Google Scholar
• Goh KK, Chen CH, Lu ML. Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials. Int J Psychiatry Clin Pract. 2019 Mar;23(1):14–32. doi: 10.1080/13651501.2018.1449864
   PubMed Web of Science ®Google Scholar
• Okuyama Y, Oya K, Matsunaga S, et al. Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2016;12:3221–3236. doi: 10.2147/NDT.S125367
   PubMed Web of Science ®Google Scholar
• Zheng W, Xiang YT, Xiang YQ, et al. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Acta Psychiatr Scand. 2016 Nov;134:(5):385–398.
   PubMed Web of Science ®Google Scholar
• Kouidrat Y, Amad A. GLP-1 agonists for metabolic disorders in schizophrenia. Schizophr Res. 2019 Feb;204:448–449. doi: 10.1016/j.schres.2018.09.019
   PubMed Web of Science ®Google Scholar
• Kouidrat Y, Amad A, Stubbs B, et al. Surgical management of obesity among people with schizophrenia and bipolar disorder: a systematic review of outcomes and recommendations for future research. Obes Surg. 2017 Jul;27:(7):1889–1895.
   PubMed Web of Science ®Google Scholar
• Noda K, Kato T, Nomura N, et al. Semaglutide is effective in type 2 diabetes and obesity with schizophrenia. Diabetol Int. 2022 Oct;13:(4):693–697.
   PubMed Web of Science ®Google Scholar
• Prasad F, De R, Korann V, et al. Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series. Ther Adv Psychopharmacol. 2023;13:20451253231165169. doi: 10.1177/20451253231165169
   Web of Science ®Google Scholar
• Gupta D, Singh A. Olanzapine-samidorphan for schizophrenia: a systematic review and meta-analysis. Indian J Psychol Med. 2023;46(1):14–23. doi: 10.1177/02537176231201326
   PubMedGoogle Scholar
• Corrao MM, Nelson LA. Olanzapine/Samidorphan: a new combination treatment for schizophrenia and bipolar I disorder intended to reduce weight gain. CNS Drugs. 2022 Jun;36(6):605–616. doi: 10.1007/s40263-022-00923-3
   PubMed Web of Science ®Google Scholar
• Jawad MY, Alnefeesi Y, Lui LMW, et al. Olanzapine and samidorphan combination treatment: a systematic review. J Affect Disord. 2022 Mar 15;301:99–106. doi: 10.1016/j.jad.2022.01.004
   PubMed Web of Science ®Google Scholar
• Peng Z, Jia Q, Mao J, et al. Effects of combined therapy of olanzapine and Samidorphan on safety and metabolic parameters in schizophrenia patients: a meta-analysis. Neuropsychiatr Dis Treat. 2023;19:2295–2308. doi: 10.2147/NDT.S426481
   PubMed Web of Science ®Google Scholar
• Tse L, Procyshyn RM, Fredrikson DH, et al. Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension. Int Clin Psychopharmacol. 2014;29(3):125–137. doi: 10.1097/YIC.0000000000000014
   PubMed Web of Science ®Google Scholar
• Jiang W-L, Cai D-B, Yin F, et al. Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Transl Psychiatry. 2020;10(1):117. doi: 10.1038/s41398-020-0785-y
   PubMed Web of Science ®Google Scholar
• Marvanova M. Strategies for prevention and management of second generation antipsychotic-induced metabolic side effects. Mental Health Clinician. 2013;3(3):154–161. doi: 10.9740/mhc.n166832
   Google Scholar
• Souaiby L, Kazour F, Zoghbi M, et al. Sexual dysfunction in patients with schizophrenia and schizoaffective disorder and its association with adherence to antipsychotic medication. J Ment Health. 2020 Dec;29:(6):623–630.
   PubMed Web of Science ®Google Scholar
• Montejo ÁL, Majadas S, Rico-Villademoros F, et al. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sex Med. 2010;7(10):3404–3413. doi: 10.1111/j.1743-6109.2010.01709.x
   PubMed Web of Science ®Google Scholar
• Rodrigues C. Management of antipsychotic-related sexual dysfunction. Eur Psychiatry. 2022;65(S1):S712–S712. doi: 10.1192/j.eurpsy.2022.1836
   Google Scholar
• Allen K, Baban A, Munjiza J, et al. Management Of antipsychotic-related sexual dysfunction: systematic review. J Sex Med. 2019 Dec;16:(12):1978–1987.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Blanco L, Greenhalgh AMD, Garcia-Rizo C, et al. Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: a meta-analysis. Schizophrenia Research. 2016 Jul;174:(1–3):156–160.
   PubMed Web of Science ®Google Scholar
• Aymerich C, Pedruzo B, Pacho M, et al. Prolactin and morning cortisol concentrations in antipsychotic naive first episode psychosis: a systematic review and meta-analysis. Psychoneuroendocrinology. 2023 Apr;150:106049. doi: 10.1016/j.psyneuen.2023.106049
   PubMed Web of Science ®Google Scholar
• Bargiota SI, Bonotis KS, Messinis IE, et al. The effects of antipsychotics on prolactin levels and Women’s menstruation. Schizophr Res Treatment. 2013;2013:1–10. doi: 10.1155/2013/502697
   Google Scholar
• Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006 Aug;65:(2):265–273.
   PubMed Web of Science ®Google Scholar
• Gorobets LN, Semenova ND, Litvinov AV. Application of antipsychotic medication: gender differences in tolerance and medication response. Jour. 2022;2(2):57–66. doi: 10.52667/2712-9179-2022-2-2-57-66
   Google Scholar
• Andrade C. Prolactin-raising and prolactin-sparing antipsychotic drugs and the risk of fracture and fragility fracture in patients with schizophrenia, dementia, and other disorders. J Clin Psychiatry. 2023 Jan 30;84(1). doi: 10.4088/JCP.23f14790
   Web of Science ®Google Scholar
• Gonzalez-Rodriguez A, Labad J, Seeman MV. Antipsychotic-induced hyperprolactinemia in aging populations: prevalence, implications, prevention and management. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jul 13;101:109941. doi: 10.1016/j.pnpbp.2020.109941
   PubMed Web of Science ®Google Scholar
• Rahman T, Sahrmann JM, Olsen MA, et al. Risk of breast cancer with prolactin elevating antipsychotic drugs: an observational study of US women (ages 18–64 years). J Clin Psychopharmacol. 2022 Jan 1;42(1):7–16. doi: 10.1097/JCP.0000000000001513
   PubMed Web of Science ®Google Scholar
• Taipale H, Solmi M, Lahteenvuo M, et al. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry. 2021 Oct;8:(10):883–891.
   PubMed Web of Science ®Google Scholar
• Montejo AL, Arango C, Bernardo M, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017 Apr;45:25–34. doi: 10.1016/j.yfrne.2017.02.003
   PubMed Web of Science ®Google Scholar
• Rusgis MM, Alabbasi AY, Nelson LA. Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option. Am J Health Syst Pharm. 2021 May 6;78(10):862–871. doi: 10.1093/ajhp/zxab065
   PubMed Web of Science ®Google Scholar
• Keks N, Hope J, Schwartz D, et al. Comparative tolerability of dopamine D2/3 receptor partial agonists for schizophrenia. CNS Drugs. 2020 May;34:(5):473–507.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Li T, Zhao L, et al. Treatment of antipsychotic-induced hyperprolactinemia: a systematic review of systematic reviews and meta-analyses. 2023.
   Google Scholar
• Labad J, Montalvo I, Gonzalez-Rodriguez A, et al. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: a systematic review and meta-analysis. Schizophr Res. 2020 Aug;222:88–96. doi: 10.1016/j.schres.2020.04.031
   PubMed Web of Science ®Google Scholar
• Fan Z, Wu Y, Shen J, et al. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res. 2013 Nov;47:(11):1549–1556.
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005 Dec;150:(6):1115–1121.
   PubMed Web of Science ®Google Scholar
• Li M, Fan YL, Tang ZY, et al. Schizophrenia and risk of stroke: a meta-analysis of cohort studies. Int J Cardiol. 2014 May 15;173(3):588–590. doi: 10.1016/j.ijcard.2014.03.101
   PubMed Web of Science ®Google Scholar
• Westman J, Eriksson SV, Gissler M, et al. Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study. Epidemiol Psychiatr Sci. 2018 Oct;27:(5):519–527.
   PubMed Web of Science ®Google Scholar
• Sweeney M, Whiskey E, Patel RK, et al. Understanding and managing cardiac side-effects of second-generation antipsychotics in the treatment of schizophrenia. BJPsych Adv. 2020;26(1):26–40. doi: 10.1192/bja.2019.49
   Google Scholar
• Rotella F, Cassioli E, Calderani E, et al. Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol. 2020 Mar;32:56–65. doi: 10.1016/j.euroneuro.2019.12.118
   PubMed Web of Science ®Google Scholar
• Wagle A. Psychotropic medications and heart. Open Acc J Biomed Sci. 2022;4(1). doi: 10.38125/OAJBS.000385
   Google Scholar
• Huhn M, Arndt T, Schneider-Thoma J, et al. Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis. Ther Adv Psychopharmacol. 2022;12:20451253221097261. doi: 10.1177/20451253221097261
   Web of Science ®Google Scholar
• Ali Z, Ismail M, Nazar Z, et al. Prevalence of QTc interval prolongation and its associated risk factors among psychiatric patients: a prospective observational study. BMC Psychiatry. 2020 Jun 3;20(1):277. doi: 10.1186/s12888-020-02687-w
   PubMed Web of Science ®Google Scholar
• Du W, Ge MW, Hu FH, et al. Qtc prolongation in patients with schizophrenia taking antipsychotics: prevalence and risk factors. J Psychopharmacol. 2023 Oct;37:(10):971–981.
   PubMed Web of Science ®Google Scholar
• Vohra J. Sudden cardiac death in schizophrenia: a review. Heart Lung Circ. 2020 Oct;29(10):1427–1432. doi: 10.1016/j.hlc.2020.07.003
   PubMed Web of Science ®Google Scholar
• Bordet C, Garcia P, Salvo F, et al. Antipsychotics and risk of QT prolongation: a pharmacovigilance study. Psychopharmacol (Berl). 2023 Jan;240:(1):199–202.
   PubMed Web of Science ®Google Scholar
• Fanoe S, Kristensen D, Fink-Jensen A, et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. Eur Heart J. 2014 May 21;35(20):1306–1315. doi: 10.1093/eurheartj/ehu100
   PubMed Web of Science ®Google Scholar
• Ruiz Diaz JC, Frenkel D, Aronow WS. The relationship between atypical antipsychotics drugs, QT interval prolongation, and torsades de pointes: implications for clinical use. Expert Opin Drug Saf. 2020 May;19(5):559–564. doi: 10.1080/14740338.2020.1745184
   PubMed Web of Science ®Google Scholar
• Gurrera RJ, Gearin PF, Love J, et al. Recognition and management of clozapine adverse effects: a systematic review and qualitative synthesis. Acta Psychiatr Scand. 2022 May;145:(5):423–441.
   PubMed Web of Science ®Google Scholar
• de Filippis R, De Fazio P, Kane JM, et al. Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome. Expert Opin Drug Saf. 2022 May;21:(5):585–587.
   PubMed Web of Science ®Google Scholar
• Correll CU, Agid O, Crespo-Facorro B, et al. A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia. CNS Drugs. 2022 Jul;36:(7):659–679.
   PubMed Web of Science ®Google Scholar
• Oloyede E, Blackman G, Whiskey E, et al. Clozapine haematological monitoring for neutropenia: a global perspective. Epidemiol Psychiatr Sci. 2022 Nov 25;31:e83. doi: 10.1017/S204579602200066X
   PubMed Web of Science ®Google Scholar
• Manu P, Sarvaiya N, Rogozea LM, et al. Benign ethnic neutropenia and clozapine use: a systematic review of the evidence and treatment recommendations. J Clin Psychiatry. 2016 Jul;77:(7):e909–16.
   PubMed Web of Science ®Google Scholar
• Aydin M, Ilhan BC, Calisir S, et al. Continuing clozapine treatment with lithium in schizophrenic patients with neutropenia or leukopenia: brief review of literature with case reports. Ther Adv Psychopharmacol. 2016 Feb;6:(1):33–38.
   PubMed Web of Science ®Google Scholar
• Corbeil O, Bechard L, Fournier E, et al. Clozapine rechallenge or continuation despite neutropenia or agranulocytosis using colony-stimulating factor: a systematic review. J Psychopharmacol. 2023 Apr;37:(4):370–377.
   PubMed Web of Science ®Google Scholar
• Myles N, Myles H, Xia S, et al. A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia. Aust N Z J Psychiatry. 2019 May;53:(5):403–412.
   PubMed Web of Science ®Google Scholar
• Myles N, Myles H, Xia S, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018 Aug;138:(2):101–109.
   PubMed Web of Science ®Google Scholar
• Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res. 2012 Nov;141:(2–3):173–178.
   PubMed Web of Science ®Google Scholar
• Vickers M, Ramineni V, Malacova E, et al. Risk factors for clozapine-induced myocarditis and cardiomyopathy: a systematic review and meta-analysis. Acta Psychiatr Scand. 2022 May;145:(5):442–455.
   PubMed Web of Science ®Google Scholar
• Yuen JW, Kim DD, Procyshyn RM, et al. A focused review of the metabolic side-effects of clozapine. Front Endocrinol. 2021;12:67. doi: 10.3389/fendo.2021.609240
   Web of Science ®Google Scholar
• Williams AM, Park SH. Seizure associated with clozapine: incidence, etiology, and management. CNS Drugs. 2015;29(2):101–111. doi: 10.1007/s40263-014-0222-y
   PubMed Web of Science ®Google Scholar
• Zheng W, Xiang Y-T, Yang X-H, et al. Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials. J Clin Psychiatry. 2017;78(5):3011. doi: 10.4088/JCP.16r10782
   Web of Science ®Google Scholar
• Solmi M, Tiihonen J, Lahteenvuo M, et al. Antipsychotics use is associated with greater adherence to cardiometabolic medications in patients with schizophrenia: results from a nationwide, within-subject design study. Schizophr Bull. 2022 Jan 21;48(1):166–175. doi: 10.1093/schbul/sbab087
   PubMed Web of Science ®Google Scholar
• Guinart D, Taipale H, Rubio JM, et al. Risk factors, incidence, and outcomes of neuroleptic malignant syndrome on long-acting injectable vs oral antipsychotics in a nationwide schizophrenia cohort. Schizophr Bull. 2021 Oct 21;47(6):1621–1630. doi: 10.1093/schbul/sbab062
   PubMed Web of Science ®Google Scholar
• Guinart D, Misawa F, Rubio JM, et al. A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatr Scand. 2021 Oct;144:(4):329–341.
   PubMed Web of Science ®Google Scholar
• Chilari M, Chianu M. Malignant neuroleptic syndrome in the use of atypical neuroleptics in the treatment of schizophrenia. 2020.
   Google Scholar
• Tse L, Barr AM, Scarapicchia V, et al. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015;13(3):395–406. doi: 10.2174/1570159X13999150424113345
   PubMed Web of Science ®Google Scholar
• Strawn JR, Keck PE Jr., Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007 Jun;164(6):870–876. doi: 10.1176/ajp.2007.164.6.870
   PubMed Web of Science ®Google Scholar
• Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs In R&D. 2015;15(1):45–62. doi: 10.1007/s40268-014-0078-0
   PubMed Web of Science ®Google Scholar
• Lao KS, Zhao J, Blais JE, et al. Antipsychotics and risk of neuroleptic malignant syndrome: a population-based cohort and case-crossover study. CNS Drugs. 2020;34(11):1165–1175. doi: 10.1007/s40263-020-00767-9
   PubMed Web of Science ®Google Scholar
• Misawa F, Okumura Y, Takeuchi Y, et al. Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: analyses based on a spontaneous reporting system database in Japan. Schizophr Res. 2021 May;231:42–46. doi: 10.1016/j.schres.2021.02.016
   PubMed Web of Science ®Google Scholar
• Langan J, Martin D, Shajahan P, et al. Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report. BMC Psychiatry. 2012 Nov 29;12(1):214. doi: 10.1186/1471-244X-12-214
   PubMedGoogle Scholar
• Schonfeldt-Lecuona C, Kuhlwilm L, Cronemeyer M, et al. Treatment of the neuroleptic malignant syndrome in international therapy guidelines: a comparative analysis. Pharmacopsychiatry. 2020 Mar;53:(2):51–59.
   PubMed Web of Science ®Google Scholar
• Pileggi DJ, Cook AM. Neuroleptic malignant syndrome: focus on treatment and rechallenge. Ann Pharmacother. 2016;50(11):973–981. doi: 10.1177/1060028016657553
   PubMed Web of Science ®Google Scholar
• Lang FU, Lang S, Becker T, et al. Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma. Psychopharmacology. 2015;232(1):1–5. doi: 10.1007/s00213-014-3807-8
   PubMed Web of Science ®Google Scholar
• Davis JM, Janicak PG, Sakkas P, et al. Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. J Ect. 1991;7(2):111–120.
   Google Scholar
• Morcos N, Rosinski A, Maixner DF. Electroconvulsive therapy for neuroleptic malignant syndrome: a case series. J Ect. 2019;35(4):225–230. doi: 10.1097/YCT.0000000000000600
   PubMed Web of Science ®Google Scholar
• Henshall C, Cipriani A, Ruvolo D, et al. Implementing a digital clinical decision support tool for side effects of antipsychotics: a focus group study. Evid Based Ment Health. 2019 May;22:(2):56–60.
   PubMed Web of Science ®Google Scholar
• Pillinger T, Howes OD, Correll CU, et al. Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development. Lancet Psychiatry. 2023 Nov;10:(11):860–876.
   PubMed Web of Science ®Google Scholar
• van Dijk F, de Wit I, Blankers M, et al. The personal antipsychotic choice index. Pharmacopsychiatry. 2018 May;51:(3):89–99.
   PubMed Web of Science ®Google Scholar
• Leucht S, Siafis S, Rodolico A, et al. Shared decision making Assistant (SDMA) and other digital tools for choosing antipsychotics in schizophrenia treatment. Eur Arch Psychiatry Clin Neurosci. 2023 Dec;273(8): 1629–1631. doi: 10.1007/s00406-023-01712-9
   PubMedGoogle Scholar
• Drake RJ, Husain N, Marshall M, et al. Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study. Lancet Psychiatry. 2020 Jul;7:(7):602–610.
   PubMed Web of Science ®Google Scholar
• Joo SW, Kim H, Jo YT, et al. Delay in psychiatric hospitalization from the diagnosis of first-episode schizophrenia and its association with clinical outcomes and direct medical costs: a nationwide, health insurance data-based study. BMC Psychiatry. 2022 Oct 8;22(1):636. doi: 10.1186/s12888-022-04292-5
   PubMed Web of Science ®Google Scholar
• Yu M, Tan Q, Wang Y, et al. Correlation between duration of untreated psychosis and long-term prognosis in chronic schizophrenia. Front Psychiatry. 2023;14:1112657. doi: 10.3389/fpsyt.2023.1112657
   PubMed Web of Science ®Google Scholar
• Correll CU, Martin A, Patel C, et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia (Heidelb). 2022 Feb 24;8(1):5. doi: 10.1038/s41537-021-00192-x
   PubMedGoogle Scholar
• Muller K, Schuster F, Rodolico A, et al. How should patient decision aids for schizophrenia treatment be designed? - a scoping review. Schizophr Res. 2023 May;255:261–273. doi: 10.1016/j.schres.2023.03.025
   PubMed Web of Science ®Google Scholar
• Blackman G, Oloyede E, Horowitz M, et al. Reducing the risk of withdrawal symptoms and relapse following clozapine discontinuation-is It feasible to develop evidence-based guidelines? Schizophr Bull. 2022 Jan 21;48(1):176–189. doi: 10.1093/schbul/sbab103
   PubMed Web of Science ®Google Scholar
• Luykx JJ, Stam N, Tanskanen A, et al. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine. Br J Psychiatry. 2020 Sep;217:(3):498–505.
   PubMed Web of Science ®Google Scholar
• Miura G, Tanaka K, Kemuriyama T, et al. Clinical outcomes after clozapine discontinuation in patients with schizophrenia: a systematic review. Pharmacopsychiatry. 2022 Jul;55:(4):181–192.
   PubMedGoogle Scholar